In this edition of JAMA Ophthalmology, Tesfaye et al report on an observational study that suggests that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may slow progression of diabetic retinopathy.
Visionary News & Insightful Strategy
Footer
A RETINA-SPECIFIC ORGANIZATION
It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.
We’ve got our eyes on working with the best retina groups and vendors in the industry.
See the best; get in touch.
Recent
- VIDEO: Home OCT offers precise retinal treatment personalization with AI
- VLOG: NeuroOp Guru: Can AI distinguish between papilledema and optic disc drusen using color fundus photos?
- VIDEO: Expert shares thoughts on gel stent implantation
- New research links retinal imaging and deep learning to improved schizophrenia detection
- Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens
Leave a Reply